Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Masashi Kanai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6954-4474; OpenAlex author ID A5015679349, A5090415788, A5152399330. Sources: OpenAlex.

Their work

Papers
27 (first author 7, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 5 papers · 2026: 3 papers

Papers 27

  1. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2025.100779↗
  2. Multi-hole Versus Fully Covered Self-expandable Metal Stents for Distal Biliary Obstruction in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002722↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Co-author DOI 10.1007/s00066-025-02433-9↗
  5. Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome. Co-author DOI 10.1007/s10147-025-02905-z↗
  6. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  7. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-024-16361-y↗
  8. Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced… Co-author DOI 10.3390/cancers17040606↗
  9. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… First author DOI 10.1093/jjco/hyae084↗
  10. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  11. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  12. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… First author DOI 10.1007/s12032-023-02011-y↗
  13. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  14. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  15. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  16. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001672↗
  17. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  18. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/s13014-018-1063-5↗
  19. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. First author DOI 10.18632/oncotarget.24865↗
  20. Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries. Last author DOI 10.1097/mpa.0000000000000891↗
  21. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Co-author DOI 10.21873/anticanres.12172↗
  22. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. First author DOI 10.1007/s10147-015-0864-x↗
  23. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.09.016↗
  24. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. First author DOI 10.1002/cam4.204↗
  25. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. First author DOI 10.1097/mpa.0000000000000050↗
  26. Therapeutic applications of curcumin for patients with pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i28.9384↗
  27. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00280-010-1470-2↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshihiko Masui · 9 shared papers, 2011–2025 · strength 0.88
  2. Junji Furuse · 6 shared papers, 2019–2026 · strength 0.84
  3. Makoto Ueno · 6 shared papers, 2019–2026 · strength 0.84
  4. Michio Yoshimura · 5 shared papers, 2022–2025 · strength 0.83
  5. Sohei Satoi · 3 shared papers, 2025–2026 · strength 0.74
  6. Tsukasa Ikeura · 3 shared papers, 2025–2026 · strength 0.74
  7. Daisuke Hashimoto · 3 shared papers, 2025–2026 · strength 0.74
  8. Masato Ozaka · 4 shared papers, 2020–2026 · strength 0.69
  9. Masafumi Ikeda · 5 shared papers, 2019–2026 · strength 0.64
  10. Chigusa Morizane · 3 shared papers, 2020–2025 · strength 0.62
  11. Yusuke Sano · 3 shared papers, 2024–2026 · strength 0.60
  12. Takashi Mizowaki · 5 shared papers, 2015–2025 · strength 0.60
  13. Kyoichi Takaori · 9 shared papers, 2014–2022 · strength 0.55
  14. Takashi Ito · 2 shared papers, 2026 · strength 0.52
  15. Makoto Naganuma · 2 shared papers, 2026 · strength 0.52
  16. Koh Nakamaru · 2 shared papers, 2026 · strength 0.52
  17. Kazuyuki Nagai · 3 shared papers, 2022–2025 · strength 0.48
  18. Etsuro Hatano · 3 shared papers, 2022–2025 · strength 0.48
  19. Akihisa Fukuda · 3 shared papers, 2022–2025 · strength 0.48
  20. So Yamaki · 2 shared papers, 2025–2026 · strength 0.45
  21. Hidetaka Miyazaki · 2 shared papers, 2025–2026 · strength 0.45
  22. Shinji Üemoto · 6 shared papers, 2014–2023 · strength 0.45
  23. Takuji Okusaka · 4 shared papers, 2019–2026 · strength 0.44
  24. Satoshi Kobayashi · 2 shared papers, 2025–2026 · strength 0.40
  25. Yukiko Takayama · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.